European Society for Medical Oncology Breast Cancer 2023

55 $

+ Include: 159 videos + 357 pdfs, size: 19.7 GB

+ Target Audience: oncologist

Description

+ Include: 159 videos + 357 pdfs, size: 19.7 GB

+ Target Audience: oncologist

+ Sample video: contact me for sample video

+ Information:

Start date 11 May 2023
End date 13 May 2023
Location Berlin, Germany

ESMO Breast Cancer 2023 took place as a hybrid meeting, onsite in Berlin, Germany, on 11-13 May 2023, and online.

ESMO Breast Cancer is a congress designed for breast cancer researchers and clinicians who have a specific interest in innovation (including translational research, new agents, molecular and functional diagnostics, biomarkers and cutting-edge research applications in the clinical setting) and care.

The 2023 edition focused on:

  • Recent developments in novel diagnostics, biomarkers and treatments in breast cancer
  • The role of antibody drug conjugates in HER2 non overexpressing breast cancers
  • New strategies for HER2 positive, luminal and triple negative breast cancers
  • Special considerations for young patients with breast cancer

The ESMO Breast Cancer Congress is a multidisciplinary meeting with a global scope, involving top scientists. This annual meeting is designed for researchers and clinicians who have a specific interest in innovation (including translational research, new agents, molecular and functional diagnostics, biomarkers and cutting-edge research applications in the clinical setting) and patient’s care.

 

 

+ Topics:

AiCME – Targeted adjuvant strategies for HR-positive Assessing risk of recurrence in HR-positive, HER2-negative early breast cancer.mp4
AiCME – Targeted adjuvant strategies for HR-positive Impact of oral targeted adjuvant therapies in patients with HR-positive, HER2-negative early breast cancer.mp4
AiCME – Targeted adjuvant strategies for HR-positive Optimizing adherence and persistence with oral targeted adjuvant therapies in HR-positive, HER2-negative early breast cancer.mp4
AiCME – Targeted adjuvant strategies for HR-positive Questions and take-home messages.mp4
AiCME – Targeted adjuvant strategies for HR-positive Shared decision-making in HR-positive, HER2-negative early breast cancer- Enhancing patient-provider communication.mp4
AiCME – Targeted adjuvant strategies for HR-positive Welcome and introductions.mp4
Beyond breast cancer Survivorship Back to work What oncologists need to know and how they could help.mp4
Beyond breast cancer Survivorship Back to work What oncologists need to know and how they could help.pdf
Beyond breast cancer Survivorship Cope with the transition Setting up a post-cancer consultation.mp4
Beyond breast cancer Survivorship Cope with the transition Setting up a post-cancer consultation.pdf
Beyond breast cancer Survivorship Q&A and discussion.mp4
Beyond breast cancer Survivorship Survivor and metavivor The role of patient organizations in accompanying the long term healing process.mp4
Beyond breast cancer Survivorship Survivor and metavivor The role of patient organizations in accompanying the long term healing process.pdf
Bringing the patient voice to cancer research (GRASP session) Adding the patient voice to science The impact on research.mp4
Bringing the patient voice to cancer research (GRASP session) Adding the patient voice to science The impact on research.pdf
Bringing the patient voice to cancer research (GRASP session) Conclusions and clinical perspectives.mp4
Bringing the patient voice to cancer research (GRASP session) Conclusions and clinical perspectives.pdf
Bringing the patient voice to cancer research (GRASP session) Formation of the Lobular Breast Cancer Alliance and Pittsburgh’s rapid autopsy programme in coordination with patient advocates.mp4
Bringing the patient voice to cancer research (GRASP session) Formation of the Lobular Breast Cancer Alliance and Pittsburgh’s rapid autopsy programme in coordination with patient advocates.pdf
Bringing the patient voice to cancer research (GRASP session) HOPE The first patient-led study for the genomic analysis of mBC.mp4
Bringing the patient voice to cancer research (GRASP session) HOPE The first patient-led study for the genomic analysis of mBC.pdf
Bringing the patient voice to cancer research (GRASP session) How GRASP is driving bidirectional learning between cancer patients and researchers.mp4
Bringing the patient voice to cancer research (GRASP session) How GRASP is driving bidirectional learning between cancer patients and researchers.pdf
ctDNA monitoring in early and advanced breast cancer ctDNA clearance during neoadjuvant treatment of breast cancer.mp4
ctDNA monitoring in early and advanced breast cancer ctDNA clearance during neoadjuvant treatment of breast cancer.pdf
ctDNA monitoring in early and advanced breast cancer ctDNA dynamics during immune checkpoint inhibition.mp4
ctDNA monitoring in early and advanced breast cancer ctDNA dynamics during immune checkpoint inhibition.pdf
ctDNA monitoring in early and advanced breast cancer ctDNA tracking in adjuvant setting for TNBC Lessons from c-TRAK trial.mp4
ctDNA monitoring in early and advanced breast cancer ctDNA tracking in adjuvant setting for TNBC Lessons from c-TRAK trial.pdf
ESMO Breast 2023 key takeaways Closure of the meeting.mp4
ESMO Breast 2023 key takeaways Early breast cancer.mp4
ESMO Breast 2023 key takeaways Early breast cancer.pdf
ESMO Breast 2023 key takeaways Metastatic breast cancer.mp4
ESMO Breast 2023 key takeaways Metastatic breast cancer.pdf
ESMO Breast 2023 key takeaways Supportive care.mp4
ESMO Breast 2023 key takeaways Supportive care.pdf
ESMO Breast 2023 key takeaways Translational research.mp4
ESMO Breast 2023 key takeaways Translational research.pdf
F. Hoffmann-La Roche PI3King the right treatment for every patient with HR+ breast cancer Introduction.mp4
F. Hoffmann-La Roche PI3King the right treatment for every patient with HR+ breast cancer PI3K A challenge to target but unmet need drives us onwards to success.mp4
F. Hoffmann-La Roche PI3King the right treatment for every patient with HR+ breast cancer PI3Kis The clinical story so far and the next chapter.mp4
F. Hoffmann-La Roche PI3King the right treatment for every patient with HR+ breast cancer Q&A discussion.mp4
final_programme_breast23hybrid.pdf
From familial to theranostic germline genetics in breast cancer Advances in imaging for early breast cancer detection among high-risk women.mp4
From familial to theranostic germline genetics in breast cancer Advances in imaging for early breast cancer detection among high-risk women.pdf
From familial to theranostic germline genetics in breast cancer Current advances in breast cancer risk assessment Prime time for a personalised approach.mp4
From familial to theranostic germline genetics in breast cancer Current advances in breast cancer risk assessment Prime time for a personalised approach.pdf
From familial to theranostic germline genetics in breast cancer Fertility issues in women with breast cancer and a germline pathogenic variant.mp4
From familial to theranostic germline genetics in breast cancer Fertility issues in women with breast cancer and a germline pathogenic variant.pdf
From familial to theranostic germline genetics in breast cancer Q&A and discussion.mp4
From familial to theranostic germline genetics in breast cancer Role of germline genetic testing in early breast cancer for therapeutic purposes.mp4
From familial to theranostic germline genetics in breast cancer Role of germline genetic testing in early breast cancer for therapeutic purposes.pdf
Gilead Sciences BREAKING THROUGH A new era of treatment for HR+HER2 mBC What do the clinical data tell us.mp4
Gilead Sciences BREAKING THROUGH Closing remarks.mp4
Gilead Sciences BREAKING THROUGH Optimal management in mTNBC What have we learned from clinical practice.mp4
Gilead Sciences BREAKING THROUGH Welcome and introduction Treatment landscape and emerging needs in metastatic breast cancer Where are we today.mp4
HER2 and beyond The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers Clinical impact of evolving ADC technology.mp4
HER2 and beyond The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers Clinical impact of evolving ADC technology.pdf
HER2 and beyond The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers Current ADC landscape.mp4
HER2 and beyond The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers Current ADC landscape.pdf
HER2 and beyond The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers Emerging toxicities and management strategies.mp4
HER2 and beyond The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers Emerging toxicities and management strategies.pdf
HER2 and beyond The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers Future directions for ADCs.mp4
HER2 and beyond The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers Future directions for ADCs.pdf
HER2 and beyond The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers Q&A and discussion.mp4
Keynote lecture Building evidence using biomarkers and new statistical methods From prevention to adjuvant treatment of breast cancer.mp4
Keynote lecture Building evidence using biomarkers and new statistical methods From prevention to adjuvant treatment of breast cancer.pdf
Keynote lecture Building evidence using biomarkers and new statistical methods Introduction by the Chair.mp4
Keynote lecture The future of early cancer detection Introduction by the Chair.mp4
Keynote lecture The future of early cancer detection.mp4
Keynote lecture The future of early cancer detection.pdf
Micrometastatic node positive disease should be considered as node-negative for systemic treatment decisions Introduction and first vote.mp4
Micrometastatic node positive disease should be considered as node-negative for systemic treatment decisions Introduction and first vote.pdf
Micrometastatic node positive disease should be considered as node-negative for systemic treatment decisions No.mp4
Micrometastatic node positive disease should be considered as node-negative for systemic treatment decisions No.pdf
Micrometastatic node positive disease should be considered as node-negative for systemic treatment decisions Second vote and conclusions.mp4
Micrometastatic node positive disease should be considered as node-negative for systemic treatment decisions Second vote and conclusions.pdf
Micrometastatic node positive disease should be considered as node-negative for systemic treatment decisions Yes.mp4
Micrometastatic node positive disease should be considered as node-negative for systemic treatment decisions Yes.pdf
Mini Oral session 1 190MO – Association of 18-Gene Expression Profile (GEP) With Clinical Outcomes in Patients With Metastatic.mp4
Mini Oral session 1 190MO – Association of 18-Gene Expression Profile (GEP) With Clinical Outcomes in Patients With Metastatic.pdf
Mini Oral session 1 191MO – KEYNOTE-355 Outcomes in patients who discontinued chemotherapy.mp4
Mini Oral session 1 191MO – KEYNOTE-355 Outcomes in patients who discontinued chemotherapy.pdf
Mini Oral session 1 1MO – Tumor immune microenvironment in ER-negative vs. ER-low, HER2-neg breast cancer.mp4
Mini Oral session 1 1MO – Tumor immune microenvironment in ER-negative vs. ER-low, HER2-neg breast cancer.pdf
Mini Oral session 1 260MO – Long term patient reported outcomes in premenopausal women.mp4
Mini Oral session 1 260MO – Long term patient reported outcomes in premenopausal women.pdf
Mini Oral session 1 93MO – Long-term patient-reported outcomes from monarchE.mp4
Mini Oral session 1 93MO – Long-term patient-reported outcomes from monarchE.pdf
Mini Oral session 1 94MO – The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer.mp4
Mini Oral session 1 94MO – The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer.pdf
Mini Oral session 1 Invited Discussant 190MO, 191MO, 1MO and 2MO.mp4
Mini Oral session 1 Invited Discussant 190MO, 191MO, 1MO and 2MO.pdf
Mini Oral session 1 Invited Discussant 93MO, 94MO and 260MO.mp4
Mini Oral session 1 Invited Discussant 93MO, 94MO and 260MO.pdf
Mini Oral session 1 Q&A and discussion 1.mp4
Mini Oral session 1 Q&A and discussion 2.mp4
Mini Oral session 2 125MO – Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P).mp4
Mini Oral session 2 125MO – Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P).pdf
Mini Oral session 2 126MO – HER2DX and pathological complete response in HER2-positive breast cancer a combined analysis of 4 neoadjuvant studies.mp4
Mini Oral session 2 126MO – HER2DX and pathological complete response in HER2-positive breast cancer a combined analysis of 4 neoadjuvant studies.pdf
Mini Oral session 2 171MO – Inflammatory profiling of individuals with germline TP53 mutations (gTP53m).mp4
Mini Oral session 2 171MO – Inflammatory profiling of individuals with germline TP53 mutations (gTP53m).pdf
Mini Oral session 2 192MO – DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC).mp4
Mini Oral session 2 192MO – DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC).pdf
Mini Oral session 2 193MO – Development of a Deep Learning model using a large real-world database.mp4
Mini Oral session 2 193MO – Development of a Deep Learning model using a large real-world database.pdf
Mini Oral session 2 3MO – HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone.mp4
Mini Oral session 2 3MO – HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone.pdf
Mini Oral session 2 4MO – Homologous recombination (HR) status of platinum responsive advanced triple negative breast cancers (aTNBC).mp4
Mini Oral session 2 4MO – Homologous recombination (HR) status of platinum responsive advanced triple negative breast cancers (aTNBC).pdf
Mini Oral session 2 95MO – Circulating tumor DNA (ctDNA) dynamics in patients (pts) receiving capecitabine (CAPE).mp4
Mini Oral session 2 95MO – Circulating tumor DNA (ctDNA) dynamics in patients (pts) receiving capecitabine (CAPE).pdf
Mini Oral session 2 Invited Discussant 125MO and 126MO.mp4
Mini Oral session 2 Invited Discussant 125MO and 126MO.pdf
Mini Oral session 2 Invited Discussant 171MO, 95MO and 3MO.mp4
Mini Oral session 2 Invited Discussant 171MO, 95MO and 3MO.pdf
Mini Oral session 2 Invited Discussant 193MO, 3MO and 192MO.mp4
Mini Oral session 2 Invited Discussant 193MO, 3MO and 192MO.pdf
Mini Oral session 2 Q&A and discussion 1.mp4
Mini Oral session 2 Q&A and discussion 2.mp4
Mini Oral session 2 Q&A and discussion 3.mp4
New algorithms for HER2 positive breast cancer New algorithm for HER2 positive mBC obtained complete clinical response (cCR).mp4
New algorithms for HER2 positive breast cancer New algorithm for HER2 positive mBC obtained complete clinical response (cCR).pdf
New algorithms for HER2 positive breast cancer New algorithm for HER2 positive mBC with brain mets.mp4
New algorithms for HER2 positive breast cancer New algorithm for HER2 positive mBC with brain mets.pdf
New algorithms for HER2 positive breast cancer New algorithm for HER2 positive mBC.mp4
New algorithms for HER2 positive breast cancer New algorithm for HER2 positive mBC.pdf
New algorithms for HER2 positive breast cancer Q&A and discussion.mp4
New comers in the early breast cancer setting Checkpoint and PARP inhibitors How to improve outcomes in those non-pCR after NACT+CPI.mp4
New comers in the early breast cancer setting Checkpoint and PARP inhibitors How to improve outcomes in those non-pCR after NACT+CPI.pdf
New comers in the early breast cancer setting Checkpoint and PARP inhibitors PARP inhibition in early breast cancer What have we learned and how can we move forward.mp4
New comers in the early breast cancer setting Checkpoint and PARP inhibitors PARP inhibition in early breast cancer What have we learned and how can we move forward.pdf
New comers in the early breast cancer setting Checkpoint and PARP inhibitors PARP inhibitor combination strategies in early breast cancer Rationale and results to date.mp4
New comers in the early breast cancer setting Checkpoint and PARP inhibitors PARP inhibitor combination strategies in early breast cancer Rationale and results to date.pdf
New comers in the early breast cancer setting Checkpoint and PARP inhibitors Q&A and discussion.mp4
New comers in the early breast cancer setting Checkpoint and PARP inhibitors Which checkpoint inhibitor, in which biomarker sub-group and when.mp4
New comers in the early breast cancer setting Checkpoint and PARP inhibitors Which checkpoint inhibitor, in which biomarker sub-group and when.pdf
Novel endocrine therapies CERAN, SERCA What to expect in the coming years.mp4
Novel endocrine therapies CERAN, SERCA What to expect in the coming years.pdf
Novel endocrine therapies Clinical implementation of oral SERD Present and future.mp4
Novel endocrine therapies Clinical implementation of oral SERD Present and future.pdf
Novel endocrine therapies Impact of molecular heterogeneity on treatment selection.mp4
Novel endocrine therapies Impact of molecular heterogeneity on treatment selection.pdf
Novel endocrine therapies PROTAC Challenges and opportunity in breast cancer.mp4
Novel endocrine therapies PROTAC Challenges and opportunity in breast cancer.pdf
Novel endocrine therapies Q&A and discussion.mp4
Omitting anthracyclines for the adjuvant treatment of early breast cancer 96MO – Omitting anthracyclines for the adjuvant treatment of patients with triple-negative breast cancer.mp4
Omitting anthracyclines for the adjuvant treatment of early breast cancer 96MO – Omitting anthracyclines for the adjuvant treatment of patients with triple-negative breast cancer.pdf
Omitting anthracyclines for the adjuvant treatment of early breast cancer Clinician’s perspective.mp4
Omitting anthracyclines for the adjuvant treatment of early breast cancer Clinician’s perspective.pdf
Omitting anthracyclines for the adjuvant treatment of early breast cancer Introduction to the topic.mp4
Omitting anthracyclines for the adjuvant treatment of early breast cancer Q&A and discussion.mp4
Optimal sequencing in advanced luminal breast cancer Emerging data on oral selective estrogen receptor degraders.mp4
Optimal sequencing in advanced luminal breast cancer Emerging data on oral selective estrogen receptor degraders.pdf
Optimal sequencing in advanced luminal breast cancer New insights on endocrine therapy resistance in luminal metastatic breast cancer.mp4
Optimal sequencing in advanced luminal breast cancer New insights on endocrine therapy resistance in luminal metastatic breast cancer.pdf
Optimal sequencing in advanced luminal breast cancer Q&A and discussion.mp4
Optimal sequencing in advanced luminal breast cancer Recent progresses on the treatment of luminal metastatic breast cancer with CDK 4 6 inhibitors.mp4
Optimal sequencing in advanced luminal breast cancer Recent progresses on the treatment of luminal metastatic breast cancer with CDK 4 6 inhibitors.pdf
Optimal treatment strategies in early breast cancer Breast conservation and axillary management after neo-adjuvant therapy.mp4
Optimal treatment strategies in early breast cancer Breast conservation and axillary management after neo-adjuvant therapy.pdf
Optimal treatment strategies in early breast cancer Optimal systemic therapy choices for HR+ HER2- pre-menopausal patients.mp4
Optimal treatment strategies in early breast cancer Optimal systemic therapy choices for HR+ HER2- pre-menopausal patients.pdf
Optimal treatment strategies in early breast cancer Q&A and discussion.mp4
Patient advocacy (Patient Advocates Working Group session) National screening programmes Patient advocate perspective.mp4
Patient advocacy (Patient Advocates Working Group session) National screening programmes Patient advocate perspective.pdf
Patient advocacy (Patient Advocates Working Group session) Q&A and discussion.mp4
Post neoadjuvant local treatment in 2023 Indications and impact of pre-post treatment imaging.mp4
Post neoadjuvant local treatment in 2023 Indications and impact of pre-post treatment imaging.pdf
Post neoadjuvant local treatment in 2023 Influence of new treatments on surgical decisions.mp4
Post neoadjuvant local treatment in 2023 Influence of new treatments on surgical decisions.pdf
Post neoadjuvant local treatment in 2023 Medical oncologist’s point of view.mp4
Post neoadjuvant local treatment in 2023 Medical oncologist’s point of view.pdf
Post neoadjuvant local treatment in 2023 Post adjuvant radiation therapy What changes.mp4
Post neoadjuvant local treatment in 2023 Post adjuvant radiation therapy What changes.pdf
Post neoadjuvant local treatment in 2023 Q&A and discussion.mp4
Poster 100P – Cost-Effectiveness Analysis of Trastuzumab Emtansine as Adjuvant Treatment for Patients.pdf
Poster 101P – Prognostic and clinical impact of the endocrine resistance sensitivity classification according to international consensus guidelines.pdf
Poster 102P – HER2DX risk-score in early-stage HER2-positive (HER2+) breast cancer.pdf
Poster 103P – Impact of Prosigna test on treatment decision in lymph node negative early breast cancer.pdf
Poster 104P – Obesity and recurrence in postmenopausal, estrogen-receptor positive breast cancer.pdf
Poster 105P – Real-world systemic treatment choices and survival outcomes of patients diagnosed.pdf
Poster 106P – Perceptions, attitudes, and behaviors towards the risk of disease recurrence among women with HER2.pdf
Poster 107P – Results in Chinese patients from pre-planned overall survival interim analysis in monarchE.pdf
Poster 108P – Safety results of post-neoadjuvant T-DM1 in the Italian compassionate use program (GIM26-TRASTHER study).pdf
Poster 109P – Updated long-term overall survival of older adjuvant ibandronate-treated patients with intermediate.pdf
Poster 10P – HER2 loss and PAM50 dynamics after neoadjuvant therapy (NAT) in HER2 positive (HER2+) early breast cancer (BC).pdf
Poster 110P – Patient preferences for adjuvant endocrine treatment of high-risk HR+HER2- breast cancer.pdf
Poster 111P – Goserelin 3 monthly depot is noninferior to Goserelin monthly depot in the treatment of Breast Cancer.pdf
Poster 112P – Correlation between HER2-negative status and risk of recurrence according to PAM50 score.pdf
Poster 113P – Breast-cancer recurrence after completing adjuvant endocrine therapy at 5 years.pdf
Poster 114P – Retrospective analysis to validate the CTS5 in patients from El Alamo IV registry and GEICAM adjuvant studies.pdf
Poster 115P – Longterm prognostic utility of MammaPrint (MP) by clinical and genomic risks, including Ultralow (gUL) risk patients (pts).pdf
Poster 116P – Time and motion randomised study of a subcutaneous (SC) pertuzumab and trastuzumab fixed-dose combination (PH FDC).pdf
Poster 117P – Age and ovarian function influence on fertility preservation attitude and outcome in breast cancer patients.pdf
Poster 118P – Real world treatment patterns and clinical outcomes among high risk, early stage HER2 negative breast cancer (BC) patients in Alberta, Canada.pdf
Poster 119TiP – A multicenter, open-label, single-arm, non-interventional real-world study to investigate the treatment.pdf
Poster 11P – Independent validation of the HER2DX assay in HER2-positive (HER2+) breast cancer (BC) treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP).pdf
Poster 120TiP – Premenopausal Women with Breast Cancer Optimally Treated with OFS (PROOFS).pdf
Poster 121TiP – LESS Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women.pdf
Poster 122TiP – Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer.pdf
Poster 127P – Exploratory biomarker (BM) analyses from IMpassion050.pdf
Poster 128P – Long-Term Outcomes of Neoadjuvant Immunotherapy plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer.pdf
Poster 129P – Impact of TROP-2 and its cellular localization on prognosis of breast cancer in the GAIN cohort.pdf
Poster 12P – HER2DX in HER2-positive (HER2+) Inflammatory Breast Cancer (IBC) a correlative analysis from a phase II clinical trial.pdf
Poster 130P – Palbociclib in combination with letrozole in HR+HER2- residual disease after standard neoadjuvant chemotherapy.pdf
Poster 131P – Efficacy of neoadjuvant letrozole and palbociclib in HER2-low vs HER2 zero luminal breast cancer.pdf
Poster 132P – Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer (BC).pdf
Poster 133P – Personalized circulating tumor DNA (ctDNA) during neoadjuvant therapy (NAT).pdf
Poster 134P – Impact of pre-operative MammaPrint BluePrint use for final treatment decisions in patients with Stage II IIIa HR+ HER2.pdf
Poster 135P – Five-year survival analysis of phase II ZoNAnTax trial Evaluation of Zoledronic-acid.pdf
Poster 136P – Clinical Implications of Non-Breast Cancer Related Findings in Breast Cancer.pdf
Poster 137P – The Evaluation of the Effect of Inflammatory-Nutritional Prognostic Scoring (INPS) System.pdf
Poster 138P – Activity and Efficacy of Neoadjuvant Chemotherapy (NACT) in Luminal-HER2 Negative Early Breast Cancer.pdf
Poster 139P – Assessing the predictive value of Systemic Inflammation Response Index (SIRI).pdf
Poster 13P – Analytical validation of HER2DX test for early-her2+ breast cancer.pdf
Poster 140P – HER2-low status and response to neoadjuvant chemotherapy and prognosis in early breast cancer.pdf
Poster 141P – Concurrent neoadjuvant endocrine therapy with chemotherapy in HR+HER2- breast cancer.pdf
Poster 142P – The predictive value of progesterone receptor expression on pCR following neoadjuvant chemotherapy in breast cancer.pdf
Poster 143P – A single institution’s real-world experience with the neoadjuvant Keynote-522 treatment regimen.pdf
Poster 144P – TRIple-Negative Breast Cancer PrOspective Registry in MiddLe East AfrIca (TRIPOLI) Study.pdf
Poster 145P – Pathological complete response in young women with breast cancer in connection with pathogenic germline BRCA1 variants and subtype.pdf
Poster 146P – Updated survival analysis in NEOPERSUR trial Neoadjuvant Pertuzumab in a real-world population in the south of Spain.pdf
Poster 147P – Germline BRCA Mutation Status and Response to Neoadjuvant Systemic Therapy in Breast Cancer.pdf
Poster 148P – Pattern of axillary lymph node involvement and scope of post neoadjuvant chemotherapy sentinel lymph.pdf
Poster 149P – HER2-low status and response to neoadjuvant chemotherapy in early breast cancer.pdf
Poster 14P – Comparison of single-cell ERBB2 mRNA expression levels with HER2 status by immunohistochemistry reveals heterogeneity of the HER2-low status.pdf
Poster 150P – Pathological complete response after neoadjuvant chemotherapy in Her2 positive breast cancer, efficacy of biosimilar compared to Herceptin.pdf
Poster 151TiP – Study in progress – Pre-Operative Oncotype DX testing A decision impact study (PRE-DX).pdf
Poster 152TiP – Trial in progress Imatinib to convert triple negative breast cancer into estrogen receptor (ER) positive breast cancer.pdf
Poster 153TiP – Effects Of Resistance vs. Aerobic Training On Ki-67 And Other Health-Related Biomarkers.pdf
Poster 154TiP – TACTIVE-N- open-label, randomized, noncomparative neoadjuvant phase 2 study of ARV-471.pdf
Poster 155TiP – ‘A randomised phase 2 trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402).pdf
Poster 156TiP – Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program).pdf
Poster 157P – Comparison of Survival Outcomes in Young Patients with Breast Cancer Receiving Contralateral Prophylactic Mastectomy Versus Unilateral Mastectomy.pdf
Poster 159P – The impact of the extent of the type of primary breast cancer (BC) surgery from the analysis of historical Italian trials.pdf
Poster 15P – Portraying HER2-positive breast cancer heterogeneity with spatial transcriptomics.pdf
Poster 160P – Malignant Phyllode tumor survival outcome of different surgical approaches.pdf
Poster 161P – DESCARTES trial De-ESCAlating RadioTherapy in patients with pathologic complete response to neoadjuvant systemic therapy.pdf
Poster 162P – The Effect of radiotherapy in primary angiosarcoma of the breast (PAOB) A SEER database analysis.pdf
Poster 163P – Long-term assessment of secondary malignancies (2ndM) in women with breast cancer (BC) and germline TP53 mutations.pdf
Poster 164P – Adjuvant Radiation Therapy Amongst Immigrant and Canadian-bornLong-term Resident Women with Breast Cancer.pdf
Poster 165P – ‘Introduction of Magseed in the -DGH Setting; no Inferiority to Wire Localisation’.pdf
Poster 166P – A mono-institutional experience of field-in-field 3D-CRT planning in breast radiotherapy with FAST and FAST-forward protocols.pdf
Poster 167P – Deep learning-based whole slide image analysis to predict sentinel node status in the INSEMA cohort.pdf
Poster 168P – Preservation versus Dissection of The Intercostobrachial Nerve for Breast Cancer Surgeries A Meta-analysis of 980 patients.pdf
Poster 169P – Hypofractionated Radiotherapy versus Conventional Radiotherapy in Postmastectomy Breast Cancer Patients.pdf
Poster 16P – Monitoring response to neoadjuvant chemotherapy in TNBC using circulating tumor DNA.pdf
Poster 170P – Comparison of the outcome between photo-medicine based dual method vs. RI method.pdf
Poster 172P – Early impact of a personalised cancer interception programme for women at non-genetic high risk of breast cancer (BC).pdf
Poster 173P – Diet, genetic predisposition and the risk of breast cancer a cohort study from the UK biobank.pdf
Poster 174P – Endocrine Disruptors and Life STILe in Patients Carrying BRCA Pathogenic VAriants With Breast.pdf
Poster 175P – Breast cancer in neurofibromatosis type 1 A retrospective review in the Portuguese population.pdf
Poster 176P – Awareness & Knowledge pertaining Genetic Breast Cancer in developing countries.pdf
Poster 177P – Oncotype DX Breast Recurrence Score (ODX RS) and gBRCAm in pts with HR+HER2.pdf
Poster 178P – Deep learning reveals spatial disorganisation of histological features in the normal breast of breast cancer patients.pdf
Poster 179P – Developing the AI program for TNBC subtyping.pdf
Poster 17P – Prognostic and predictive non-invasive biomarkers in early Triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT).pdf
Poster 180P – Improving the referral pathway for breast cancer patients Lessons learnt from 1-year pilot.pdf
Poster 181P – Male breast cancer (MBC) familial history (FH), clinicopathological (CP) characteristics, oncogenetic (OG) testing and outcome in a cohort of 98 patients (pts).pdf
Poster 182P – Association of non-genetic factors with breast cancer risk in genetically predisposed groups of women in the UK Biobank cohort.pdf
Poster 183P – Clinical characteristics of early onset BRCA1-mut breast cancer with different HER2-negative molecular subtypes.pdf
Poster 184P – PGS000508 as a Prediction for Breast Cancer Risk in Taiwanese Populations.pdf
Poster 18P – A translational project of the WSG-ADAPT-TN Trial demonstrates immunomodulatory and anti-viral defense gene networks predicting pathological.pdf
Poster 194P – Safety outcomes by UGT1A1 status in the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in HR+HER2.pdf
Poster 195P – Impact of an interactive eHealth system for patient reported outcomes on safety in patients with hormone receptor positive.pdf
Poster 196P – Efficacy and safety of first-line (1L) ribociclib (RIB) + letrozole (LET) in patients (pts).pdf
Poster 197P – ATREZZO TRIAL (SOLTI-1907) A Phase II trial targeting estrogen receptor negative or PAM50 non-luminal disease.pdf
Poster 198P – Relationship of diarrhea and neutropenia events with outcomes in patients (pts) with metastatic triple-negative breast cancer.pdf
Poster 199P – Correlation of circulating tumor DNA (ctDNA) or Thymidine Kinase activity (TKa) Dynamic Patterns with tumor response in patients.pdf
Poster 19P – Tumor-associated microbiome composition and response to neoadjuvant chemotherapy (NACT) in early triple negative breast cancer (TNBC).pdf
Poster 200P – OlympiAD exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC).pdf
Poster 201P – Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC) Preliminary phase 2 results.pdf
Poster 202P – A phase 1b2 study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD).pdf
Poster 203P – Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level.pdf
Poster 204P – Phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer.pdf
Poster 205P – VERITAC update phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor.pdf
Poster 206P – Capivasertib (C) + palbociclib (P) and fulvestrant (F) in patients (pts) with HR+HER2 advanced breast cancer (ABC).pdf
Poster 207P – A doublet metronomic chemotherapeutic regimen with oral vinorelbine and capecitabine (mNC) in patients with metastatic HER2-negative breast cancer.pdf
Poster 208P – Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases.pdf
Poster 209P – Trastuzumab plus lapatinib or chemotherapy in patients with HER2-positive advanced breast cancer refractory to anti-HER2 therapies.pdf
Poster 20P – Spatial Analysis of Residual Tumor Tissue Provides New Clues for Post-Neoadjuvant Treatment Approaches in Triple Negative Breast Cancer.pdf
Poster 210P – Real-world outcomes in patients (pts) with HR+HER2- metastatic breast cancer (mBC) and germline tumour BRCA mutations.pdf
Poster 211P – ER-low breast cancer evolution from primary tumor to relapse and prognostic impact.pdf
Poster 212P – Real world progression-free survival 2 with CDK46 inhibitors plus endocrine therapy and subsequent line.pdf
Poster 213P – Real-World Clinical Outcomes Associated with First-Line Palbociclib and Aromatase Inhibitor Therapy Among Patients.pdf
Poster 214P – Delphi consensus on the definition of visceral crisis in advanced breast cancer among French Breast Cancer Intergroup Unicancer.pdf
Poster 215P – Impact of Her2 Low on Survival in Patients Treated with Standard Therapies in Advanced Breast Cancer.pdf
Poster 216P – Sacituzumab govitecan in metastatic triple negative breast cancer efficacy -with a focus on brain metastases and toxicity in a real-world cohort.pdf
Poster 217P – Incidence and outcome of brain and or leptomeningeal metastatic disease in HER2-low breast cancer in the French ESME cohort.pdf
Poster 218P – Characteristics and outcomes of HER2-low (H-Low) and HER2-zero (H-0) advanced breast cancer (ABC) patients (pts) from GEICAM.pdf
Poster 219P – Chemotherapy use and survival outcomes for patients diagnosed with metastatic hormone receptor-positive.pdf
Poster 21P – Evaluation of breast cancer stem cell (BCSC) subpopulation and immunogenicity profile in triple-negative breast cancer.pdf
Poster 220P – Oral Selective Estrogen Receptor Degraders for metastatic hormone receptor-positive, HER2 negative breast cancer according to ESR1 mutation.pdf
Poster 221P – HERmione, a crossed-view survey about patients living with metastatic HER2-positive Breast Cancer.pdf
Poster 222P – Real-world clinical outcomes among patients (pts) with metastatic advanced triple-negative breast cancer.pdf
Poster 223P – Real-World Effectiveness of Palbociclib (Pal) Plus an Aromatase Inhibitor (AI) vs AI Alone in Patients.pdf
Poster 224P – Clinical features and outcomes in HER2+ mBC patients treated with Trastuzumab deruxtecan.pdf
Poster 225P – Platinum-based chemotherapy and PARP Inhibitors for BRCA mutated metastatic breast cancer (LATER-BC).pdf
Poster 226P – Treatment Patterns and Comorbidities in Patients With HR+HER2- MBC A Real-World Study in Five European Countries.pdf
Poster 227P – Molecular landscape of patients with early relapsed metastatic triple-negative breast cancer.pdf
Poster 228P – The impact of initial tumor response to docetaxel, trastuzumab, and pertuzumab.pdf
Poster 22P – PD-L1 testing in mTNBC Interplatform and interobserver reproducibility of CE-IVD assays for CPS and IC scores.pdf
Poster 230P – Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer a multicenter study.pdf
Poster 231P – Trastuzumab Deruxtecan for the treatment of metastatic breast cancer in the UK real world data.pdf
Poster 232P – Real World Study of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer in the United Kingdom.pdf
Poster 233P – Treatment pattern and outcomes for the first two lines of chemotherapy in patients diagnosed with metastatic triple negative breast cancer.pdf
Poster 234P – Real-World Treatment Patterns and Outcomes of Patients Receiving Palbociclib Plus Endocrine Therapy in Spain.pdf
Poster 236P – Trastuzumab deruxtecan in italian real-world experience updated analysis from DE-REAL study.pdf
Poster 237P – Real-world safety and efficacy of Trastuzumab-Deruxtecan (T-DXd) in HER2-positive advanced breast cancer (ABC).pdf
Poster 238P – Real-world treatment (Tx) patterns in patients (pts) with HR+HER2- metastatic breast cancer.pdf
Poster 239P – Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma.pdf
Poster 23P – Prognostic value of tumor infiltrating lymphocytes (TILs) and soluble immune checkpoints in early Triple negative breast cancer (TNBC).pdf
Poster 240P – Effect of Dose Intensity (DI) of Palbociclib (PAB) and initial body weight dosage (BWD) on progression free survival (PFS).pdf
Poster 241P – APOBEC3-induced PIK3CA mutations predict better clinical outcomes with PI3K inhibitors in patients with PIK3CA-mutated advanced breast cancer.pdf
Poster 242P – Cyclin-dependent kinases inhibitors and dermatological reactions.pdf
Poster 243P – Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in metastatic breast cancer patients.pdf
Poster 244P – Eribulin in Chinese advanced breast cancer patient intolerant to first second-line taxane-based therapy.pdf
Poster 245P – Abemaciclib for Treating Patients with HR+, HER2- Advanced Metastatic Breast Cancer in the UK A Real World Study.pdf
Poster 246P – Correlation of MIB1 Labeling Index and Hormone Receptor Status with Survival in Metastatic Breast Cancer Patients Treated.pdf
Poster 247P – Efficacy of therapy directed against PI3K and cyclin inhibitors based on the location of PI3K mutations.pdf
Poster 248P – Systemic treatment strategies following progression on CDK4 6 inhibitors in advanced breast cancer.pdf
Poster 249P – A retrospective review of patients receiving trastuzumab deruxtecan across five centres in Ireland.pdf
Poster 24P – Associating BRCA1 hypermethylation with clinicopathological and molecular variables in triple-negative breast cancer.pdf
Poster 250P – Liver Toxicity (LT) in patients (pts) with ER-positive HER2-negative Metastatic Breast Cancer.pdf
Poster 251P – The Effect of Hormone Receptor Positive Percentage On Treatment Response And Prognosis In HR+ HER2- Metastatic Breast Cancer Receiving CDK.pdf
Poster 252P – Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 Negative.pdf
Poster 253P – Immunopheresis to Remove Soluble TNF Receptors as a Novel Immunotherapy for Patients with Advanced Breast Cancer.pdf
Poster 254P – The invasive lobular cancer of the breast (ILC)- a collection of clinical and pathological data in patients with (non-)metastatic breast cancer (BC).pdf
Poster 255TiP – AIPAC-003- A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3).pdf
Poster 256TiP – TACTIVE-E- phase 1b study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader.pdf
Poster 257TiP – VERITAC-2- a global, randomized phase 3 study of ARV-471, a PROteolysis TArgeting Chimera.pdf
Poster 258TiP – A phase 2 trial of loperamide (L) and granulocyte colony-stimulating factors (G-CSF) to improve sacituzumab govitecan.pdf
Poster 259TiP – Treatment of Oligometastatic Breast Cancer (OMBC) – a randomised phase 3 trial comparing Stereotactic Ablative Radiotherapy.pdf
Poster 25P – Combining tissue microarray analysis with RNA-Sequencing to explore Platelet-derived growth factor-CC biology in primary triple-negative breast cancer.pdf
Poster 261P – The Long-term Melatonin Administration and Cancer Fatigue in Breast Cancer Patients.pdf
Poster 262P – Breast cancer survivors and healthy women could gut microbiota make a difference.pdf
Poster 263P – Cross-sectional nationwide population-based study of living conditions, and identification of sexual and fertility profiles among young women.pdf
Poster 264P – Impact of a cardio-oncology rehabilitation framework among high cardiovascular risk breast cancer survivors.pdf
Poster 265P – UCATS A national specialist service for integration of gender affirming and oncological care in transgender patients with breast cancer.pdf
Poster 267P – Ultrasound-Guided Injection With or Without Rehabilitation Exercise in Breast Cancer Survivors.pdf
Poster 268P – Effects of Aroma Lymphatic Tressage on Lower Extremity Edema by Taxane-based Chemotherapy and Quality of Life in Patients with Breast Cancer.pdf
Poster 269P – Treatment for vasomotor symptoms in women on adjuvant endocrine therapy after breast cancer.pdf
Poster 26P – ctDNA prognostic and diagnostic value for recurrence in patients with early-stage breast cancer A systematic review and meta-analysis.pdf
Poster 270P – Real-world data of cardiac disorders screening in breast cancer survivors.pdf
Poster 271P – Impact of COVID-19 vaccination on health-related quality of life in patients with breast cancer.pdf
Poster 272P – Competitive cause of death in Elderly breast cancer survivors.pdf
Poster 273P – Effect of adjuvant chemotherapy on sarcopenia in early breast cancer patients.pdf
Poster 274P – Racial and ethnic disparities in breast cancer mortality in women with and without diabetes between 2005 and 2020.pdf
Poster 275P – Serological response to COVID-19 vaccine in patients with advanced breast cancer.pdf
Poster 276P – Safety of pregnancy after early breast cancer in young women with hormone receptor-positive disease a systematic review and meta-analysis.pdf
Poster 277TiP – OASIS 4 study design a Phase 3 trial assessing the efficacy and safety of elinzanetant in the treatment.pdf
Poster 27P – Quantitative detection of plasma extracellular vesicles in early and metastatic breast cancer patients using SiMoA technology.pdf
Poster 28P – Rational thresholding of circulating tumor DNA copy number for early detection of disease progression in advanced metastatic breast cancer.pdf
Poster 29P – Prevalence of high tumor mutational burden (TMB) in patients with metastatic breast cancer (mBC) assessed by liquid biopsy (LB).pdf
Poster 30P – Comparison of commercially available gene expression signatures in older patients with early breast cancer.pdf
Poster 31P – C-reactive protein as a prognostic factor in early breast cancer.pdf
Poster 32P – Improvement of Diagnostic Accuracy of Breast Cancer Using Multi-protein Signature Markers through Machine Learning.pdf
Poster 33P – Antitumor activity of TROP2 Antibody Drug Conjugate Datopotamab Deruxtecan in Chemotherapy-Resistant Breast Cancer Models.pdf
Poster 34P – Investigating morphological heterogeneity in luminal breast cancer integrating artificial intelligence and spatial transcriptomics.pdf
Poster 35P – SNPs of aromatase gene (CYP19A1) and outcomes of patients with estrogen receptor-positive.pdf
Poster 36P – Megestrol Acetate resistance in Estrogen Receptor Positive Advanced Breast Cancer in the MEGA trial.pdf
Poster 37P – Enhanced tumor-immunity drives resistance to CDK4 6 inhibitors in advanced breast cancer.pdf
Poster 38P – Assessment of lipidomic profile in Endocrine Receptor positive (ER+) MBC patients treated with CDK 4 6 inhibitors (CDKi) and endocrine therapy (ET).pdf
Poster 39P – A validation study of a self-testing capillary kit, the rhelise kit for therapeutic dose monitoring.pdf
Poster 40P – Stromal tumor infiltrating lymphocytic infiltration in hormone receptor-positive HER2-negative (HR+HER2-) metastatic breast cancer (BC).pdf
Poster 41P – Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model.pdf
Poster 42P – Conflicting results of BCL2 based on HER2 status in patients with breast cancer.pdf
Poster 43P – AKT and estrogen receptor (ER) inhibition potently impairs endocrine resistance (EndoR) in breast cancer (BC).pdf
Poster 44P – Comparison of biological characteristics in relation to survival in luminal invasive lobular vs invasive non-lobular breast carcinomas.pdf
Poster 45P – A three-gene signature marks the time to loco-regional recurrence in luminal-like breast cancer.pdf
Poster 46P – PIK3CA mutation impact in prognosis of advanced HR+HER2 negative breast cancer patients.pdf
Poster 47P – PIK3CA mutational status in tissue & plasma and clinicopathological features in HR+HER2- breast cancer patients.pdf
Poster 48P – An AI System for accurate Ki-67 IHC Assessment in Breast Cancer following the IKWG Whole Section Global Scoring Protocol.pdf
Poster 49P – Metformin is associated with increased intratumoural immune infiltrates in patients with primary invasive breast cancer.pdf
Poster 50P – HER2HER3 heterodimerization can define ER+HER2-low breast cancer as a distinct biological entity.pdf
Poster 51P – Clinical and biological significance of low ERBB2 expression in ductal carcinoma in situ (DCIS) of the breast.pdf
Poster 52P – Clinical characterization of HER2 low in patients with lobular breast cancer (ILC).pdf
Poster 53P – HER2 low by immunohistochemistry (IHC) and gene expression by qRT-PCR using OncotypeDX in ER+ early breast cancer.pdf
Poster 54P – Proficiency testing for HER2-low expression in breast cancer.pdf
Poster 55P – Clinicopathological and molecular changes induced by neoadjuvant therapy (NAT) in hormone receptor-positive.pdf
Poster 56P – Association between HER2 expression level and prognosis using RT-PCR in HER2-low breast cancer.pdf
Poster 57P – Clinicopathologic Landscape of High Risk Early Stage HER2-Low Breast Cancer.pdf
Poster 58P – Quantitative indicators of TREC and KREC excision rings in breast cancer.pdf
Poster 59P – Tumor cells-adipocytes interactions are associated with poor disease outcome in invasive lobular carcinoma.pdf
Poster 5P – HER2DX risk-score in HER2-positive (HER2+) breast cancer following neoadjuvant and adjuvant anti-HER2-based treatment an updated survival analysis.pdf
Poster 60P – Deep learning-based digital pathology for risk stratification of atypical ductal hyperplasia ductal carcinoma in situ.pdf
Poster 61P – Genomic risk and gene expression-based inference of anti-cancer drugs vulnerability in early breast cancer.pdf
Poster 62P – KI67 in ER+HER2negative pure invasive lobular breast carcinoma (ILC) What’s the best Ki67 threshold to differentiate prognosis.pdf
Poster 63P – Ki67 values and MammaPrint (MP) genomic risk in Early Breast Cancer Correlation by ductal vs lobular histology.pdf
Poster 64P – Baseline characteristics associated with Ki67 drop after neoadjuvant endocrine therapy in patients with HR+HER2- early breast cancer.pdf
Poster 65P – Association of the Digistain Prognostic Score with outcomes in patients with HR- positive HER2-negative breast cancer.pdf
Poster 66P – Digital Profiling of Immune Biomarkers Relation to Anthracycline Benefit.pdf
Poster 67P – The utility of a deep learning-based approach in HER-2neu assessment in breast cancer.pdf
Poster 69P – Chasing the origin of 23 recurrent BRCA1 mutations in Pakistani breast and ovarian cancer patients.pdf
Poster 6P – Combined analysis of the HER2DX genomic tool in adjuvant APT and ATEMPT trials.pdf
Poster 70P – Invasive lobular breast cancer (ILC), an overlooked subtype in clinical trials.pdf
Poster 71P – microRNA (miRNA) a Putative Biomarker to Better Define the Molecular Apocrine Breast Cancer (MABC) Subtype.pdf
Poster 72P – Correlation of serum cytokine patterns and clinicopathological factors in breast carcinoma patients.pdf
Poster 73P – Frequent discordance in PD-L1 and PD-L2 protein expression in breast cancer.pdf
Poster 74P – Transcriptomic profile identifies biological differences in very young women with breast cancer.pdf
Poster 75P – Electronic patient-reported outcomes and machine learning in predicting unplanned visits.pdf
Poster 76P – Using Bioinformatics and Artificial Intelligence (AI) to Map the Cyclin-dependent Kinase 46 Inhibitor (CDK46i) Translational Biomarker Landscape.pdf
Poster 77P – BRCA mutations may induce immune-resistance in breast cancer patients treated with IO-only approach a retrospective analysis.pdf
Poster 78P – Multiplex immunohistochemistry and digital pathology analysis examining the prevalence and prognostic value of tertiary lymphoid structures.pdf
Poster 79P – Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide.pdf
Poster 7P – Independent validation of HER2DX ERBB2 mRNA score to predict HER2-positive (HER2+), HER2-low and HER2-0 status in breast cancer.pdf
Poster 80P – Trop-2 expression and its role as a prognostic factor in patients with luminal early breast cancer.pdf
Poster 81P – Genetic association of ABCG2 polymorphisms on triple-negative breast cancer susceptibility and prognosis.pdf
Poster 82P – Variability Of Biological Parameters Between Tumor Biopsies And Surgical Samples In Breast Cancer Patients.pdf
Poster 83P – Exoxomes and miRNA in Breast cancer cancerogenesis a case-control study.pdf
Poster 84P – Clinicopathological features and cause-specific survival of salivary gland-like tumors of the breast.pdf
Poster 85P – Microbiome analysis in patients with breast cancer via an oral prebiotics therapy.pdf
Poster 86P – Phyllodes tumours understanding more about the unknown.pdf
Poster 87P – Breaking Down the Divide- An Analysis of Male Breast Cancer Demographics and Survival by Race in United States.pdf
Poster 88P – Male Breast Cancer – A Rare Conundrum.pdf
Poster 89P – Inclusion of racial and ethnic minorities in European Breast Cancer Clinical Trials.pdf
Poster 8P – First decision impact study of HER2DX in patients (pts) with HER2-positive (HER2+) early breast cancer.pdf
Poster 90P – Is physician-patient language concordance better for clinical trial enrollment in breast cancer patients A real- life study.pdf
Poster 91P – The lack of documentation of patient’s body mass index (BMI) in recent clinical trials.pdf
Poster 92P – The impact of a micro CME activity on physician knowledge and competence regarding new data in the early and metastatic breast cancer.pdf
Poster 97P – Efficacy and safety of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection.pdf
Poster 98P – Real-world effectiveness and safety of neratinib in the extended adjuvant treatment of patients with HER2.pdf
Poster 99P – Exploratory analysis of differential gene expression (DGE) and non-negative matrix factorisation (NMF) clustering in KATHERINE.pdf
Poster 9P – Prognostic Value of Baseline Neutrophil Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer Exploratory analysis from the CLEOPATRA trial.pdf
Precision personalised breast cancer medicine Adjusting treatment to patient adiposity.mp4
Precision personalised breast cancer medicine Adjusting treatment to patient adiposity.pdf
Precision personalised breast cancer medicine Lessons learned from large omics-based screening programmes.mp4
Precision personalised breast cancer medicine Lessons learned from large omics-based screening programmes.pdf
Precision personalised breast cancer medicine Q&A and discussion.mp4
Precision personalised breast cancer medicine Refining diagnosis and treatment of lobular breast cancer.mp4
Precision personalised breast cancer medicine Refining diagnosis and treatment of lobular breast cancer.pdf
Precision personalised breast cancer medicine Tissue or liquid Assessing your marker of interest.mp4
Precision personalised breast cancer medicine Tissue or liquid Assessing your marker of interest.pdf
Proffered Paper session 1 185O – Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC).mp4
Proffered Paper session 1 185O – Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC).pdf
Proffered Paper session 1 186O – Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase 3 study.mp4
Proffered Paper session 1 186O – Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase 3 study.pdf
Proffered Paper session 1 187O – Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+ HER2.mp4
Proffered Paper session 1 187O – Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+ HER2.pdf
Proffered Paper session 1 188O – EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+ HER2.mp4
Proffered Paper session 1 188O – EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+ HER2.pdf
Proffered Paper session 1 Invited Discussant 185O and 186O.mp4
Proffered Paper session 1 Invited Discussant 185O and 186O.pdf
Proffered Paper session 1 Invited Discussant 187O and 188O.mp4
Proffered Paper session 1 Invited Discussant 187O and 188O.pdf
Proffered Paper session 1 Q&A and discussion 1.mp4
Proffered Paper session 1 Q&A and discussion 2.mp4
Proffered Paper session 2 123O – Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2.mp4
Proffered Paper session 2 123O – Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2.pdf
Proffered Paper session 2 124O – Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive HER2-negative (HR+ HER2).mp4
Proffered Paper session 2 124O – Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive HER2-negative (HR+ HER2).pdf
Proffered Paper session 2 189O – A phase 2 Study of Patritumab Deruxtecan (HER3-DXd), in patients (pts).mp4
Proffered Paper session 2 189O – A phase 2 Study of Patritumab Deruxtecan (HER3-DXd), in patients (pts).pdf
Proffered Paper session 2 Invited Discussant 124O and 189O.mp4
Proffered Paper session 2 Invited Discussant 124O and 189O.pdf
Proffered Paper session 2 Invited Discussant LBA1 and 123O.mp4
Proffered Paper session 2 Invited Discussant LBA1 and 123O.pdf
Proffered Paper session 2 LBA1 – Final analysis of the placebo-controlled randomised phase 3 IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo).mp4
Proffered Paper session 2 LBA1 – Final analysis of the placebo-controlled randomised phase 3 IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo).pdf
Proffered Paper session 2 Q&A and discussion 1.mp4
Proffered Paper session 2 Q&A and discussion 2.mp4
Refining checkpoint inhibition in triple-negative breast cancer (TNBC) Benefits of IO in early and metastatic breast cancer.mp4
Refining checkpoint inhibition in triple-negative breast cancer (TNBC) Benefits of IO in early and metastatic breast cancer.pdf
Refining checkpoint inhibition in triple-negative breast cancer (TNBC) Can we predict and manage toxicity in the real world.mp4
Refining checkpoint inhibition in triple-negative breast cancer (TNBC) Can we predict and manage toxicity in the real world.pdf
Refining checkpoint inhibition in triple-negative breast cancer (TNBC) Q&A and discussion.mp4
Refining checkpoint inhibition in triple-negative breast cancer (TNBC) What’s on the horizon for immunotherapy for TNBC.mp4
Refining checkpoint inhibition in triple-negative breast cancer (TNBC) What’s on the horizon for immunotherapy for TNBC.pdf
Refining checkpoint inhibition in triple-negative breast cancer (TNBC) Who really benefits from IO.mp4
Refining checkpoint inhibition in triple-negative breast cancer (TNBC) Who really benefits from IO.pdf
Seagen Case by case Evolving treatment landscape.mp4
Seagen Case by case Optimizing outcomes for patients with CNS relapse (case-based discussion).mp4
Seagen Case by case Progression after T-DXd What to do in 3L (case-based discussion).mp4
Seagen Case by case Q&A Key takeaways.mp4
Seagen Case by case Welcome and introductions.mp4
Selecting biomarkers to inform neoadjuvant strategies Gene-expression profiling to guide neoadjuvant treatment in HR+HER2 breast cancer.mp4
Selecting biomarkers to inform neoadjuvant strategies Gene-expression profiling to guide neoadjuvant treatment in HR+HER2 breast cancer.pdf
Selecting biomarkers to inform neoadjuvant strategies Points to consider in the development of biomarkers in the neoadjuvant setting.mp4
Selecting biomarkers to inform neoadjuvant strategies Points to consider in the development of biomarkers in the neoadjuvant setting.pdf
Selecting biomarkers to inform neoadjuvant strategies Q&A and discussion.mp4
Targeted options for advanced luminal breast cancers Digital interactions in the management of targeted treatment.mp4
Targeted options for advanced luminal breast cancers Digital interactions in the management of targeted treatment.pdf
Targeted options for advanced luminal breast cancers From SERMs to SERDs Advances and challenges in the development of novel agents.mp4
Targeted options for advanced luminal breast cancers From SERMs to SERDs Advances and challenges in the development of novel agents.pdf
Targeted options for advanced luminal breast cancers Luminal HER2 positive vs luminal HER2 negative.mp4
Targeted options for advanced luminal breast cancers Luminal HER2 positive vs luminal HER2 negative.pdf
Targeted options for advanced luminal breast cancers Next generation tyrosine kinase inhibitors.mp4
Targeted options for advanced luminal breast cancers Next generation tyrosine kinase inhibitors.pdf
Targeted options for advanced luminal breast cancers Q&A and discussion.mp4
Utility of real-world data Comparative prognostic studies from real-world data Real or not real.mp4
Utility of real-world data Comparative prognostic studies from real-world data Real or not real.pdf
Utility of real-world data ESMO GROW Methodological guidance for reporting oncology real-world evidence.mp4
Utility of real-world data ESMO GROW Methodological guidance for reporting oncology real-world evidence.pdf
Utility of real-world data Q&A and discussion.mp4
Utility of real-world data Quality, cost and survival Can real-world data help to solve the equation.mp4
Utility of real-world data Quality, cost and survival Can real-world data help to solve the equation.pdf
Utility of real-world data Real-world data Towards achieving the achievable in cancer care.mp4
Utility of real-world data Real-world data Towards achieving the achievable in cancer care.pdf
Welcome to the ESMO Breast Cancer 2023 and 2023 award lecture Introduction to the ESMO Breast Cancer 2023 award lecture.mp4
Welcome to the ESMO Breast Cancer 2023 and 2023 award lecture Opening session.mp4
Welcome to the ESMO Breast Cancer 2023 and 2023 award lecture Opening session.pdf
Welcome to the ESMO Breast Cancer 2023 and 2023 award lecture Progress through challenging dogma.mp4
Welcome to the ESMO Breast Cancer 2023 and 2023 award lecture Progress through challenging dogma.pdf
YO Clinical case discussion Case 1 Detection of treatment toxicity through remote monitoring.mp4
YO Clinical case discussion Case 1 Detection of treatment toxicity through remote monitoring.pdf
YO Clinical case discussion Case 2 Triple-negative early breast cancer in monozygotic twins.mp4
YO Clinical case discussion Case 2 Triple-negative early breast cancer in monozygotic twins.pdf
YO Clinical case discussion Case 3 Management of brain metastases in metastatic breast cancer treated with antibody-drug conjugates.mp4
YO Clinical case discussion Case 3 Management of brain metastases in metastatic breast cancer treated with antibody-drug conjugates.pdf
YO Clinical case discussion Mentor guided discussion 1.mp4
YO Clinical case discussion Mentor guided discussion 2.mp4
YO Clinical case discussion Mentor guided discussion 3.mp4
YO Clinical case discussion Mentor guided discussion 3.pdf
YO Clinical case discussion Q&A and general discussion.mp4

Reviews

There are no reviews yet.

Be the first to review “European Society for Medical Oncology Breast Cancer 2023”

Your email address will not be published. Required fields are marked *